Spermosens AB (publ) ("Spermosens" or the "Company") is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of claims compared to Spermosens' first US patent.

This patent includes claims for a biosensor utilizing the JUNO protein immobilized on a variety of substrates, significantly expanding the scope beyond the previously patented dish, microbead, or electrode substrates. The biosensor is designed to detect or quantify sperm function, offering novel insights into male fertility diagnostics.

Upon grant, Spermosens will hold two US patents, further strengthening its intellectual property portfolio and positioning the Company for future partnerships in the assisted reproductive technology (ART) sector. These patents represent a key milestone in Spermosens' mission to enhance male fertility diagnostics and deliver groundbreaking solutions for IVF clinics and other stakeholders in the reproductive health industry.

Tore Duvold, CEO of Spermosens, comments: "This second US patent reinforces our technological foundation and strengthens our ability to collaborate with leading partners in the ART field. The broader scope of claims not only underscores the innovative nature of our JUNO-Checked technology but also opens up new opportunities for commercialization and future development."

The patent is expected to be formally granted early 2025. Spermosens also holds patent protection in other key markets, including Europe and Japan.

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com